Provided by Tiger Trade Technology Pte. Ltd.

Phathom Pharmaceuticals

6.92
-0.1600-2.26%
Post-market: 6.990.0700+1.01%19:30 EDT
Volume:1.68M
Turnover:11.72M
Market Cap:559.83M
PE:-5.47
High:7.23
Open:7.20
Low:6.82
Close:7.08
52wk High:18.31
52wk Low:6.82
Shares:80.90M
Float Shares:63.93M
Volume Ratio:1.49
T/O Rate:2.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2659
EPS(LYR):-3.0342
ROE:-3489.00%
ROA:-8.80%
PB:-1.63
PE(LYR):-2.28

Loading ...

Phathom Begins Phase 3 Trial of Voquezna As-Needed Dosing in Non-Erosive GERD Patients

Reuters
·
Sep 29

Phathom Pharmaceuticals, - Topline Results from Phase 3 Study Expected in Q1 2028

THOMSON REUTERS
·
Sep 29

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of Voquezna® (Vonoprazan) for As-Needed Treatment of Non-Erosive Gerd

THOMSON REUTERS
·
Sep 29

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

GlobeNewswire
·
Sep 29

H.C. Wainwright Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)

TIPRANKS
·
Sep 22

Phathom Pharmaceuticals Initiated at Market Perform by Leerink Partners

Dow Jones
·
Sep 09

Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT

MT Newswires Live
·
Sep 09

Phathom Pharmaceuticals initiated with a Market Perform at Leerink

TIPRANKS
·
Sep 09

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 01

Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Aug 17

Phathom Pharmaceuticals’ Earnings Call Signals Profitable Growth

TIPRANKS
·
Aug 16

Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough

Simply Wall St.
·
Aug 01

Phathom Pharmaceuticals is Maintained at Buy by Needham

Dow Jones
·
Jul 31

Phathom Pharmaceuticals price target lowered to $22 from $28 at Needham

TIPRANKS
·
Jul 31

Phathom Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Phathom Pharmaceuticals Down over 19%, on Track for Largest Percent Decrease Since May 2025

Dow Jones
·
Jul 31

Phathom Pharmaceuticals Q2 Revenue Beats on Voquezna Prescription Growth

Reuters
·
Jul 30

Phathom Q2 GAAP Net Loss Narrows to $17.6 Million from Year-ago; Revenue Rises 88% to $74.3 Million

Reuters
·
Jul 30

Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M Estimate

Benzinga Earnings
·
Jul 30

Phathom Pharmaceuticals Outlook FY Revenue USD 310-325 Million VS. Ibes Estimate USD 332.2 Million

THOMSON REUTERS
·
Jul 30